UCL DIVISION OF MEDICINE

2013

• Denton CP, Ong VH (2013). Targeted therapies for systemic sclerosis.. Nat Rev Rheumatol, , - . doi:10.1038/nrrheum.2013.46
• Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, Denton CP (2013). Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.. QJM, , - . doi:10.1093/qjmed/hct111
• De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA (2013). Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.. J Rheumatol, 40(4), 435 - 446. doi:10.3899/jrheum.120725
• Carmona FD, Cénit MC, Diaz-Gallo LM, Broen JC, Simeón CP, Carreira PE, Callejas-Rubio JL, Fonollosa V, López-Longo FJ, González-Gay MA, Hunzelmann N, Riemekasten G, Witte T, Kreuter A, Distler JH, Madhok R, Shiels P, van Laar JM, Schuerwegh AJ, Vonk MC, Voskuyl AE, Fonseca C, Denton CP, Herrick A, Worthington J, Arnett FC, Tan FK, Assassi S, Radstake TR, Mayes MD, Martín J, Spanish Scleroderma Group (2013). New insight on the Xq28 association with systemic sclerosis.. Ann Rheum Dis, , - . doi:10.1136/annrheumdis-2012-202742
• Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG (2013). Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.. Am J Cardiol, 111(2), 278 - 285. doi:10.1016/j.amjcard.2012.09.031
• van Laar JM, Nihtyanova SI, Naraghi K, Denton CP, Tyndall A (2013). Autologous HSCT for systemic sclerosis.. Lancet, 381(9883), 2079 - 2080. doi:10.1016/S0140-6736(13)61239-8
• Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Lindahl GE, Renzoni EA (2013). Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.. Thorax, 68(5), 436 - 441. doi:10.1136/thoraxjnl-2012-201786
• Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, Müller-Ladner U, Pope JE, Vonk MC, Doelberg M, Chadha-Boreham H, Heinzl H, Rosenberg DM, McLaughlin VV, Seibold JR, on behalf of the DETECT study group (2013). Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.. Ann Rheum Dis, , - . doi:10.1136/annrheumdis-2013-203301
• Gilbane AJ, Denton CP, Holmes AM (2013). Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells.. Arthritis Res Ther, 15(3), 215 - . doi:10.1186/ar4230
• Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, Carreira PE, Vargas S, Román-Ivorra JA, González-Gay MA, Tolosa C, López-Longo FJ, Espinosa G, Vicente EF, Hesselstrand R, Riemekasten G, Witte T, Distler JH, Voskuyl AE, Schuerwegh AJ, Shiels PG, Nordin A, Padyukov L, Hoffmann-Vold AM, Scorza R, Lunardi C, Airo P, van Laar JM, Hunzelmann N, Gathof BS, Kreuter A, Herrick A, Worthington J, Denton CP, Zhou X, Arnett FC, Fonseca C, Koeleman BP, Assasi S, Radstake TR, Mayes MD, Martín J, Spanish Scleroderma Group (2013). Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility.. Ann Rheum Dis, 72(7), 1233 - 1238. doi:10.1136/annrheumdis-2012-202357
• Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG (2013). Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.. Arthritis Rheum, 65(4), 1074 - 1084. doi:10.1002/art.37838

2012

• Derrett-Smith E, Hoyles R, Khan K, Abraham DJ, Denton CP (2012). Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis..
• Watson JM, Buniak JN, Shiwen X, Abraham DJ, Denton CP, Stratton RJ (2012). Role of Endosomal and Cell Membrane Toll-Like Receptors in Keratinocyte Activation by Systemic Sclerosis Autoantibodies..
• Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR, Scleroderma Clinical Trials Consortium (2012). Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.. Arthritis Rheum, 64(10), 3420 - 3429. doi:10.1002/art.34427
• Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ (2012). Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts.. Rheumatology (Oxford), 51(12), 2146 - 2154. doi:10.1093/rheumatology/kes234
• Broen JC, Bossini-Castillo L, van Bon L, Vonk MC, Knaapen H, Beretta L, Rueda B, Hesselstrand R, Herrick A, Worthington J, Hunzelman N, Denton CP, Fonseca C, Riemekasten G, Kiener HP, Scorza R, Simeón CP, Ortego-Centeno N, Gonzalez-Gay MA, Airò P, Coenen MJ, Martín J, Radstake TR, Spanish Systemic Sclerosis Group (2012). A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators.. Arthritis Rheum, 64(1), 264 - 271. doi:10.1002/art.33325
• Moinzadeh P, Denton CP, Abraham D, Ong V, Hunzelmann N, Eckes B, Krieg T (2012). Biomarkers for skin involvement and fibrotic activity in scleroderma.. J Eur Acad Dermatol Venereol, 26(3), 267 - 276. doi:10.1111/j.1468-3083.2011.04206.x
• Bossini-Castillo L, Simeon CP, Beretta L, Broen JC, Vonk MC, Ríos-Fernández R, Espinosa G, Carreira P, Camps MT, Castillo MJ, González-Gay MA, Beltrán E, Carmen Freire MD, Narváez J, Tolosa C, Witte T, Kreuter A, Schuerwegh AJ, Hoffmann-Vold AM, Hesselstrand R, Lunardi C, van Laar JM, Chee MM, Herrick A, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Martin J, Spanish Scleroderma Group (2012). A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis.. Arthritis Res Ther, 14(2), R85 - . doi:10.1186/ar3809
• Chighizola C, Meroni PL, Schreiber BE, Coghlan JG, Denton CP, Ong VH (2012). Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients.. Clin Exp Rheumatol, 30(2 Suppl 71), S81 - S85.
• Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U, EUSTAR Co-authors (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.. Ann Rheum Dis, 71(8), 1355 - 1360. doi:10.1136/annrheumdis-2011-200742
• Chung L, Denton CP, Distler O, Furst DE, Khanna D, Merkel PA, Scleroderma Clinical Trials Consortium (2012). Clinical trial design in scleroderma: where are we and where do we go next?. Clin Exp Rheumatol, 30(2 Suppl 71), S97 - 102.
• Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X, Denton CP (2012). Gut fibrosis with altered colonic contractility in a mouse model of scleroderma.. Rheumatology (Oxford), 51(11), 1989 - 1998. doi:10.1093/rheumatology/kes191
• Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Renzoni EA (2012). Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.. Eur Respir J, 40(3), 641 - 648. doi:10.1183/09031936.00163911
• Chighizola C, Meroni PL, Schreiber BE, Coghlan JG, Denton CP, Ong VH (2012). Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 30(2), S81 - S85.
• Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP (2012). Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.. Clin Rev Allergy Immunol, 43(3), 249 - 255. doi:10.1007/s12016-012-8331-1
• Moinzadeh P, Khan K, Ong VH, Denton CP (2012). Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapy.. Rheumatology (Oxford), 51(12), 2296 - 2298. doi:10.1093/rheumatology/kes137
• Moinzadeh P, Howell K, Ong V, Nihtyanova S, Denton CP (2012). IMPACT OF ANA SUBTYPE ON PROGRESSION FROM ISOLATED RP TO SSC: IMPLICATIONS FOR CLASSIFICATION AND EARLY DIAGNOSIS.
• Denton CP (2012). SCLERODERMA IN MEN.
• Moinzadeh P, Fonseca C, Khan K, Abraham D, Ong V, Denton CP (2012). IL7 AXIS IN SSC: ANALYSIS OF LIGAND AND RECEPTOR SNP POLYMORPHISMS AND SERUM IL7 LEVELS.
• Derrett-Smith E, Hoyles R, Moinzadeh P, Chighizola C, Khan K, Ong V, Abraham D, Denton CP (2012). EXPRESSION PROFILING OF SKIN AND LUNG TISSUE AND EXPLANTED FIBROBLASTS IN THE T beta RII Delta K-FIB TRANSGENIC MOUSE MODEL OF SCLERODERMA.
• Moinzadeh P, Fonseca C, Hellmich M, Shah A, Chighizola C, Denton CP, Ong V (2012). ASSOCIATION OF SYSTEMIC SCLEROSIS WITH DIFFERENT AUTOANTIBODY SUBGROUPS AND MALIGNANCIES: A RETROSPECTIVE REGISTRY-BASED UK COHORT STUDY.
• Khan K, Shiwen X, Abraham D, Denton CP, Ong V (2012). IMPACT OF IL-6 TRANS-SIGNALLING IN DRIVING FIBROSIS VIA JAK2/STAT3 SIGNALLING PATHWAYS IN EARLY DCSSC.
• Warrell CE, Dobarro D, Handler C, Denton CP, Schreiber BE, Coghlan JG (2012). IS THERE AN ASSOCIATION BETWEEN WARFARIN AND SURVIVAL IN SSC-PAH PATIENTS TREATED WITH FIRST-LINE BOSENTAN MONOTHERAPY?.
• Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH (2012). Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.. Ann Rheum Dis, 71(7), 1235 - 1242. doi:10.1136/annrheumdis-2011-200955
• Donovan J, Denton CP, Norman J, Abraham DA (2012). ANALYSIS OF SPECIFIC PDGFR alpha AND PDGFR beta SIGNAL TRANSDUCTION PATHWAYS IN SSc FIBROBLASTS AND EXAMINATION OF CUTANEOUS WOUND HEALING AND FIBROSIS IN A PDGFR alpha KNOCKOUT MOUSE.
• Tam A, Sonnylal S, Leask A, Denton CP, de Crombrugghe B, Norman J, Abraham DJ (2012). EPITHELIAL-TO-MESENCHYMAL TRANSITION AND LUNG FIBROSIS.
• Khan K, Thoua N, Dooley A, Derrett-Smith E, Ong V, Abraham DJ, Denton CP (2012). GUT FIBROSIS IS ASSOCIATED WITH REDUCED COLONIC CONTRACTILITY IN A TGF-beta MOUSE MODEL.
• Fonseca C, Ahmed B, Ong V, Denton CP, Abraham D (2012). ANALYSIS OF A POLYMORPHISM (RS763361) IN THE CD226 GENE IN UK PATIENTS WITH SSc.
• Khan K, Shiwen X, Abraham DJ, Denton CP, Ong V (2012). OVEREXPRESSION OF IL-6 IN EARLY dcSSc MAY DRIVE FIBROTIC RESPONSE VIA JAK2/STAT3 SIGNALLING PATHWAYS.
• Moinzadeh P, Fonseca C, Abraham DJ, Ong VH, Denton CP (2012). ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE IL-7R AND IL-7 GENE IN SSc PATIENTS.
• Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, Matucci-Cerinic M, DUO Registry investigators (2012). Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry.. Ann Rheum Dis, 71(5), 718 - 721. doi:10.1136/annrheumdis-2011-200631
• Alcacer-Pitarch B, Buch MH, Gray J, Denton CP, Herrick A, Navarro-Coy N, Collier H, Loughrey L, Pavitt S, Siddle HJ, Wright J, Helliwell PS, Emery P, Redmond AC (2012). Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol. BMC MUSCULOSKELETAL DISORDERS, 13, - . doi:10.1186/1471-2474-13-11
• Sullivan KM, Wigley FM, Denton CP, van Laar JM, Furst DE (2012). Haemopoietic stem-cell transplantation for systemic sclerosis. LANCET, 379(9812), 219 - 219.
• Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV (2012). Fecal incontinence in systemic sclerosis is secondary to neuropathy.. Am J Gastroenterol, 107(4), 597 - 603. doi:10.1038/ajg.2011.399
• Buniak JN, Denton CP, Abraham DJ, Stratton RJ (2012). Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis..
• Trinder SL, Gilbane A, Ponticos M, Donovan J, Denton CP, Abraham DJ, Holmes AM (2012). A Putative Role for the TGF beta Accessory Receptors Betaglycan and Endoglin in pulmonary Complications of Scleroderma..
• Ngcozana T, Parker L, Denton CP, Ong V (2012). The Impact of Sexual Difficulties in Women with Scleroderma and Interpersonal Relationships.
• Carreira PE, Carmona L, Joven BE, Denton CP, Allanore Y, Walker UA, Matucci-Cerinic M, Mueller-Ladner U, Eustar (2012). Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database..
• Schreiber BE, Keir G, Dobarro D, Handler C, Nihtyanova S, Suntharaligam J, Sverzelatti N, Robinson G, Hansell D, Wells AU, Denton CP, Coghlan JG (2012). Systemic Sclerosis Associated Pulmonary Hypertension - Is Pulmonary Veno-Occlusive Disease As Common As They Say?.
• Nihtyanova SI, Ong VH, Denton CP (2012). Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis..
• Webber M, Dobarro D, Handler C, Denton CP, Schreiber BE, Coghlan JG (2012). Inflammatory Muscle Disease Associated Pulmonary Hypertension - Clinical Features and Survival At a National Referral Centre..
• Saketkoo LA, Huscher D, Khanna D, Dellaripa PF, Flaherty K, Oddis CV, Phillips K, Wells AU, Denton CP, Distler O, Kowal-Bielecka OM, Christmann R, Sandorfi N, Pittrow D, Strand V, Seibold JR, Brown KK, Matteson EL (2012). Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains..
• Domsic RT, Nihtyanova S, Wisniewski SR, Fine MJ, Kwoh CK, Denton CP, Jr MTA (2012). External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients..
• Nihtyanova SI, Ong VH, Denton CP (2012). Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis..
• Quillinan NP, McIntosh D, Haq S, Denton CP (2012). A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy.
• Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D (2012). Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.. Arthritis Care Res (Hoboken), 64(3), 351 - 357. doi:10.1002/acr.20679

2011

• Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR (2011). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.. Ann Rheum Dis, 70(1), 32 - 38. doi:10.1136/ard.2010.130658
• Goh NS, Desai SR, Anagnostopoulos C, Hansell DM, Hoyles RK, Sato H, Denton CP, Black CM, du Bois RM, Wells AU (2011). Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.. Eur Respir J, 38(1), 184 - 190. doi:10.1183/09031936.00010910
• Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, Vázquez-Abad MD, Denton CP (2011). Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.. Arthritis Rheum, 63(3), 775 - 782. doi:10.1002/art.30195
• Amin K, Clarke A, Sivakumar B, Puri A, Fox Z, Brough V, Denton CP, Peter EM, Butler P (2011). The psychological impact of facial changes in scleroderma.. Psychol Health Med, 16(3), 304 - 312. doi:10.1080/13548506.2010.540250
• Thoua NM, Schizas A, Forbes A, Denton CP, Emmanuel AV (2011). Internal anal sphincter atrophy in patients with systemic sclerosis.. Rheumatology (Oxford), 50(9), 1596 - 1602. doi:10.1093/rheumatology/ker153
• Chen Y, Leask A, Abraham DJ, Kennedy L, Shi-Wen X, Denton CP, Black CM, Verjee LS, Eastwood M (2011). Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.. Fibrogenesis Tissue Repair, 4(1), 9 - . doi:10.1186/1755-1536-4-9
• Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van 't Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, González-Escribano MF, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels PG, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie BA, Hoffmann-Vold AM, Palm O, García de la Peña P, Carreira P, Spanish Scleroderma Group , Varga J, Hinchcliff M, Lee AT, Gourh P, Amos CI, Wigley FM, Hummers LK, Nelson JL, Riemekasten G, Herrick A, Beretta L, Fonseca C, Denton CP, Gregersen PK, Agarwal S, Assassi S, Tan FK, Arnett FC, Radstake TR, Mayes MD, Martin J (2011). Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.. PLoS Genet, 7(7), e1002178 - . doi:10.1371/journal.pgen.1002178
• Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, Denton CP, Coghlan JG (2011). Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.. Arthritis Rheum, 63(11), 3531 - 3539. doi:10.1002/art.30535
• Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (2011). Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).. J Rheumatol, 38(11), 2419 - 2427. doi:10.3899/jrheum.110344
• Saketkoo LA, Huscher D, Khanna D, Dellaripa PF, Flaherty K, Matteson EL, Oddis CV, Phillips K, Wells AU, Denton CP, Distler O, Kowal-Bielecka OM, Pittrow D, Christmann R, Sandorfi N, Strand V, Brown KK, Seibold JR (2011). Developing a Disease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise.
• Derrett-Smith E, Hoyles R, Moinzadeh P, Chighizola CB, Khan K, Ong V, Abraham DJ, Denton CP (2011). Expression Profiling of Skin and Lung Tissue and Explanted Fibroblasts in a Transgenic Mouse Model of Scleroderma.
• Schreiber BE, Valerio C, Keir G, Handler C, Wells AU, Denton CP, Coghlan JG (2011). Diffusion of Carbon Monoxide Predicts Survival in Systemic Sclerosis Patients with Pulmonary Hypertension and Interstitial Lung Disease.
• Chighizola CB, Moinzadeh P, Khan K, Wood TA, Meroni PL, Abraham DJ, Whitfield ML, Ong V, Denton CP (2011). Identification of a Gene Expression Signature in Limited Cutaneous Systemic Sclerosis That Includes Several Vascular Genetic Factors.
• Khan K, Shi-wen X, Abraham DJ, Denton CP, Ong V (2011). Enhanced IL-6 Trans-Signalling in Early dcSSc May Drive Fibrotic Response Via JAK2/STAT3 Signalling Pathways.
• Thoua N, Khan K, Dooley A, Derrett-Smith E, Denton CP (2011). Gut Fibrosis with Associated Diminished Colonic Contractility in a Transgenic Mouse Model of Scleroderma. Arthritis and Rheumatism, 63(10), S585 - S585.
• Derrett-Smith E, Dooley A, Baliga R, Hobbs A, Abraham DJ, Denton CP (2011). Intermittent Systemic VEGF Inhibition Induces Pulmonary Arterial Hypertension In a Transgenic Mouse Model of Scleroderma. Arthritis and Rheumatism, 63(10), S1022 - S1023.
• Denton CP, Hachulla E (2011). Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening.. Eur Respir Rev, 20(122), 270 - 276. doi:10.1183/09059180.00006111
• Denton CP, Hoyles RK, Derrett-Smith E, Abraham DJ (2011). Tissue-Specific Knockout/Knockdown of Type 2 TGF-beta Receptor and Protection against Bleomycin Injury/Fibrosis. AM J RESP CRIT CARE, 184(8), 983 - 984.
• Parapuram SK, Xu SW, Elliott C, Welch ID, Jones H, Baron M, Denton CP, Abraham DJ, Leask A (2011). Loss of PTEN Expression by Dermal Fibroblasts Causes Skin Fibrosis. J INVEST DERMATOL, 131(10), 1996 - 2003. doi:10.1038/jid.2011.156
• Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (2011). Clinical and serological hallmarks of systemic sclerosis overlap syndromes.. J Rheumatol, 38(11), 2406 - 2409. doi:10.3899/jrheum.101248
• McCann MR, Monemdjou R, Ghassemi-Kakroodi P, Fahmi H, Perez G, Liu SX, Xu SW, Parapuram SK, Kojima F, Denton CP, Abraham DJ, Martel-Pelletier J, Crofford LJ, Leask A, Kapoor M (2011). mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis (vol 13, pg 402, 2011). ARTHRITIS RES THER, 13(2), - . doi:10.1186/ar3285
• Holmes AM, Ponticos M, Shi-Wen X, Denton CP, Abraham DJ (2011). Elevated CCN2 expression in scleroderma: a putative role for the TGFβ accessory receptors TGFβRIII and endoglin.. J Cell Commun Signal, 5(3), 173 - 177. doi:10.1007/s12079-011-0140-4
• Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O (2011). Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.. Arthritis Res Ther, 13(3), 114 - . doi:10.1186/ar3346
• Tan A, Denton CP, Mikhailidis DP, Seifalian AM (2011). Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review. CLIN EXP RHEUMATOL, 29(2), S66 - S74.
• McCann MR, Monemdjou R, Ghassemi-Kakroodi P, Fahmi H, Perez G, Liu SX, Xu SW, Parapuram SK, Kojima F, Denton CP, Abraham DJ, Martel-Pelletier J, Crofford LJ, Leask A, Kapoor M (2011). mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. ARTHRITIS RES THER, 13(1), - . doi:10.1186/ar3226
• Ngcozana T, Denton CP, Black CM, Parker L, Brough G, Ong V (2011). A STUDY OF SEXUAL DYSFUNCTION AMONGST MEN WITH SYSTEMIC SCLEROSIS IN THE UK: PREVALENCE AND PSYCHOLOGICAL IMPACT.
• Galluccio F, Walker UA, Nihtyanova S, Moinzadeh P, Hunzelmann N, Krieg T, Steen V, Baron M, Sampaio-Barros P, Kayser C, Nash P, Denton CP, Tyndall A, Muller-Ladner U, Matucci-Cerinic M (2011). Registries in systemic sclerosis: a worldwide experience. RHEUMATOLOGY, 50(1), 60 - 68. doi:10.1093/rheumatology/keq355
• Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP (2011). An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor.. Am J Respir Crit Care Med, 183(2), 249 - 261. doi:10.1164/rccm.201002-0279OC

2010

• Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, EPOSS Group (2010). Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.. J Rheumatol, 37(1), 105 - 115. doi:10.3899/jrheum.090661
• Shi-Wen X, Eastwood M, Denton CP, Leask A, Abraham DJ (2010). The PPAR gamma agonist rosiglitazone reverses the persistent fibrotic phenotype of scleroderma fibroblasts.
• Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP (2010). Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.. QJM, 103(2), 109 - 115. doi:10.1093/qjmed/hcp174
• Nihtyanova SI, Denton CP (2010). Autoantibodies as predictive tools in systemic sclerosis.. Nat Rev Rheumatol, 6(2), 112 - 116. doi:10.1038/nrrheum.2009.238
• Herrick AL, Lunt M, Silman AJ, Denton CP (2010). Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.. Rheumatology (Oxford), 49(8), 1607 - 1608. doi:10.1093/rheumatology/keq115
• Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE, EPOSS Group (2010). Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group.. Ann Rheum Dis, 69(7), 1360 - 1363. doi:10.1136/ard.2009.120303
• Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM (2010). Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.. Arthritis Rheum, 62(7), 2101 - 2108. doi:10.1002/art.27466
• Khanna D, Denton CP (2010). Evidence-based management of rapidly progressing systemic sclerosis.. Best Pract Res Clin Rheumatol, 24(3), 387 - 400. doi:10.1016/j.berh.2009.12.002
• Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, EPOSS-OMERACT Group (2010). Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.. Clin Exp Rheumatol, 28(2 Suppl 58), S47 - S52.
• Hachulla E, Denton CP (2010). Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.. Eur Respir Rev, 19(118), 314 - 320. doi:10.1183/09059180.00007810
• Sivakumar B, Haloob N, Puri A, Latif A, Ghani S, Brough V, Molloy J, Clarke A, Denton CP, Butler PE (2010). Systemic sclerosis as a model of chronic rejection in facial composite tissue transplantation.. J Plast Reconstr Aesthet Surg, 63(10), 1669 - 1676. doi:10.1016/j.bjps.2009.08.020
• Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG (2010). Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.. Rheumatology (Oxford), 49(11), 2147 - 2153. doi:10.1093/rheumatology/keq241
• Pantelidis P, Fonseca C, DeWan A, Wu A, Woodhead F, Futema M, Abraham D, Renzoni E, Sackler R, Denton CP, Wells A, Welsh KI, Hoh J, Black CM (2010). Genome-wide association study (GWAS) in a UK systemic sclerosis cohort.
• Blumbach K, Zweers MC, Brunner G, Peters AS, Schulz JN, Denton CP, Fassler R, Krieg T, Eckes B (2010). INTEGRIN-LINKED KINASE CONTROLS MYOFIBROBLAST DIFFERENTIATION VIA RHOA/ROCK ACTIVITY AND TGF-beta LEVELS. WOUND REPAIR REGEN, 18(6), A80 - A80.
• Renzoni EA, Shi-Wen X, Nicholson AG, Maher TM, Dusmet M, Suleman-Verjee L, Eastwood M, Parapuram SK, Leask A, Wells AU, Denton CP, Abraham DJ (2010). Upregulation of angiotensin signalling pathways underlies the increased contractility observed in pulmonary fibrosis lung fibroblasts. CLIN EXP RHEUMATOL, 28(5), S74 - S74.
• Dooley A, Xu SW, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer KR (2010). Effects of the green tea antioxidant epigallocatechin-3-gallate on collagen production and fibroblast activity in systemic sclerosis. CLIN EXP RHEUMATOL, 28(5), S64 - S64.
• Jones H, Derrett-Smith E, Denton CP, Abraham D, Bou-Gharios G, So P (2010). Non-invasive imaging for the assessment of dermal fibrosis. CLIN EXP RHEUMATOL, 28(5), S67 - S67.
• Derrett-Smith EC, Dooley A, Baliga R, Hobbs A, MacAllister R, Abraham D, Denton CP (2010). Perturbed VEGF signalling within the pulmonary vasculature of a TGF beta dependent mouse model of systemic sclerosis. CLIN EXP RHEUMATOL, 28(5), S63 - S63.
• Chighizola C, Nithyanova S, Meroni PL, Coghlan G, Denton CP, Ong V (2010). Role of n-terminal pro-bnp in detecting heart involvement in systemic sclerosis patients. CLIN EXP RHEUMATOL, 28(5), S61 - S61.
• Lindahl GE, Shi-Wen X, Aggrey-Fynn G, Norman JT, Denton CP, Abraham DJ, Wells AU, Renzoni EA (2010). Global gene expression profiling of scleroderma lung fibroblasts identifies a heterogeneous expression pattern of activated genes and consistent repression of interferon related pathways. CLIN EXP RHEUMATOL, 28(5), S69 - S69.
• Xu SW, Tam A, Sonnylal S, Stratton R, Leask A, Denton CP, Norman J, de Crombrugghe B, Abraham DJ (2010). Epithelial to mesenchymal switching in the pathogenesis of systemic sclerosis. CLIN EXP RHEUMATOL, 28(5), S82 - S82.
• Pantelidis P, Fonseca C, DeWan A, Wu C, Woodhead F, Futema M, Kwok L, Abraham D, Renzoni E, Sackler R, Denton CP, Wells A, Welsh K, Hoh J, Black CM (2010). Genome-wide association study in UK systemic sclerosis cohort. CLIN EXP RHEUMATOL, 28(5), S73 - S73.
• Khan K, Hoyles RK, Shiwen X, Derrett-Smith E, Abraham DJ, Denton CP (2010). Fibrocyte recruitment and myofibroblast diffrentiation after acute lung injury is blocked by selective inhibition of tgfbeta signalling in resident interstitial fibroblasts. CLIN EXP RHEUMATOL, 28(5), S68 - S68.
• Blumbach K, Zweers MC, Brunner G, Peters AS, Schmitz M, Schulz JN, Schild A, Denton CP, Sakai T, Fassler R, Krieg T, Eckes B (2010). Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts - role of TGF beta 1 levels and RhoA activity. J CELL SCI, 123(22), 3872 - 3883. doi:10.1242/jcs.063024
• Liu SX, Xu SW, Blumbach K, Eastwood M, Denton CP, Eckes B, Krieg T, Abraham DJ, Leask A (2010). Expression of integrin beta 1 by fibroblasts is required for tissue repair in vivo. J CELL SCI, 123(21), 3674 - 3682. doi:10.1242/jcs.070672
• Blumbach K, Zweers MC, Brunner G, Peters AS, Schmitz M, Schulz JN, Denton CP, Fassler R, Krieg T, Eckes B (2010). Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts - role of RhoA/ROCK signaling and TGF beta 1 levels.
• Foeldvari I, Nihtyanova SI, Wierk A, Denton CP (2010). Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort.. J Rheumatol, 37(11), 2422 - 2426. doi:10.3899/jrheum.100001
• Ong VH, Denton CP (2010). Innovative therapies for systemic sclerosis.. Curr Opin Rheumatol, 22(3), 264 - 272. doi:10.1097/BOR.0b013e328337c3d6
• Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ (2010). Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.. Rheumatology (Oxford), 49(2), 259 - 263. doi:10.1093/rheumatology/kep371
• Zolnowska M, Ponticos M, Pantelidis P, Denton CP, Abraham D, Fonseca C (2010). ANALYSIS OF POLYMORPHISMS IN THE HOMEOBOX TRANSCRIPTION FACTOR NKX2-5 GENE IN PATIENTS WITH SYSTEMIC SCLEROSIS. CLIN EXP RHEUMATOL, 28(2), S139 - S139.
• Khan K, Hoyles R, Derrett-Smith F, Shiwen X, Abraham D, Denton CP (2010). SELECTIVE INHIBITION OF TGFBETA SIGNALLING IN RESIDENT PULMONARY FIBROBLASTS BLOCKS FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG INJURY. CLIN EXP RHEUMATOL, 28(2), S103 - S103.
• Weber E, Rossi A, Sozio F, Sestini P, Renzoni EA, Khan K, Denton CP, Abraham DJ (2010). MORPHOMETRIC EVALUATION OF LYMPHATIC AND BLOOD VESSELS IN SCLERODERMA SKIN. CLIN EXP RHEUMATOL, 28(2), S97 - S97.
• Xu S, Eastwood M, Stratton R, Denton CP, Abraham D, Leask A (2010). ROSIGLITAZONE ALLEVIATES THE PERSISTENT FIBROTIC PHENOTYPE OF LESIONAL SKIN SCLERODERMA FIBROBLASTS. CLIN EXP RHEUMATOL, 28(2), S97 - S97.
• Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP (2010). Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.. Rheumatology (Oxford), 49(9), 1770 - 1775. doi:10.1093/rheumatology/keq147
• Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer R (2010). Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.. Rheumatology (Oxford), 49(11), 2024 - 2036. doi:10.1093/rheumatology/keq208
• Jones H, Derrett-Smith E, Shiwen X, Khan K, Denton CP, Abraham D, Bou-Gharios G, So P (2010). NON-INVASIVE IMAGING FOR THE ASSESSMENT OF DERMAL FIBROSIS.
• Derrett-Smith EC, Baliga R, Dooley A, Khan K, Shi-Wen X, Abraham D, Denton CP (2010). FIBROBLAST-SPECIFIC ACTIVATION OF TGF beta IN VIVO RECAPITULATES A HYPOXIC PULMONARY HYPERTENSION PHENOTYPE IN MICE.
• Khan K, Hoyles RK, Xu SW, Derrett-Smith E, Abraham D, Denton CP (2010). FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG INJURY IS BLOCKED BY SELECTIVE INHIBITION OF TGF beta SIGNALING IN RESIDENT INTERSTITIAL FIBROBLASTS.
• Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP (2010). Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.. Arthritis Res Ther, 12(2), R69 - . doi:10.1186/ar2986
• Coghlan JG, Pope J, Denton CP (2010). Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. CURR OPIN PULM MED, 16, S27 - S34. doi:10.1097/01.mcp.0000370208.45756.e8
• Aden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM, Denton CP, Abraham DJ, Stratton RJ (2010). Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.. J Invest Dermatol, 130(9), 2191 - 2200. doi:10.1038/jid.2010.120
• Rossi A, Sozio F, Sestini P, Renzoni EA, Khan K, Denton CP, Abraham DJ, Weber E (2010). Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. HUM PATHOL, 41(3), 366 - 374. doi:10.1016/j.humpath.2009.08.009
• Eastwood M, Shi-wen X, Denton CP, Renzoni E, Abraham DJ (2010). Altered gene expression in fibroblasts cultured in 3-D collagen lattices subjected to biomechanical load.
• Eastwood M, Chen Y, Shi-wen X, Denton CP, Black CM, Abraham DJ (2010). Thrombospondin 1-a key mediator of matrix contraction depend on MEK/ERK in SSc pathogenesis.
• Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, Denton CP (2010). Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.. J Rheumatol, 37(1), 116 - 124. doi:10.3899/jrheum.090668

2009

• Walker UA, Tyndall A, Czirják L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Matucci-Cerinic M, EUSTAR co-authors (2009). Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database.. Ann Rheum Dis, 68(6), 856 - 862. doi:10.1136/ard.2008.091348
• Derrett-Smith EC, Dooley A, Khan K, Xu SW, De Winter P, Abraham D, Denton CP (2009). VASCULOPATHY IN A TGF-beta DEPENDENT MOUSE MODEL OF SYSTEMIC SCLEROSIS.
• Herrick AL, Roberts C, Tracey A, Silman A, Anderson M, Goodfield M, McHugh N, Muir L, Denton CP (2009). Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis.. Arthritis Rheum, 60(3), 878 - 882. doi:10.1002/art.24333
• Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R (2009). Updated clinical classification of pulmonary hypertension.. J Am Coll Cardiol, 54(1 Suppl), S43 - S54. doi:10.1016/j.jacc.2009.04.012
• Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP (2009). A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis.. Rheumatology (Oxford), 48(10), 1218 - 1221. doi:10.1093/rheumatology/kep215
• Quillinan NP, Denton CP (2009). Disease-modifying treatment in systemic sclerosis: current status.. Curr Opin Rheumatol, 21(6), 636 - 641. doi:10.1097/BOR.0b013e3283310d57
• Denton CP, Derrett-Smith EC (2009). Juvenile-onset systemic sclerosis: children are not small adults.. Rheumatology (Oxford), 48(2), 96 - 97. doi:10.1093/rheumatology/ken418
• Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE (2009). Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.. Arthritis Rheum, 60(7), 2142 - 2155. doi:10.1002/art.24620
• Xu SW, Liu S, Eastwood M, Sonnylal S, Denton CP, Abraham DJ, Leask A (2009). Rac inhibition reverses the phenotype of fibrotic fibroblasts.. PLoS One, 4(10), e7438 - . doi:10.1371/journal.pone.0007438
• Pakozdi A, Wilson H, Black CM, Denton CP (2009). Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clin Exp Rheumatol, 27(3 Suppl 54), 5 - 8.
• Derrett-Smith EC, Denton CP, Sonnylal S (2009). Animal models of scleroderma: lessons from transgenic and knockout mice.. Curr Opin Rheumatol, 21(6), 630 - 635. doi:10.1097/BOR.0b013e32833130c1
• Howell KJ, Lavorato A, Visentin MT, Smith RE, Schaefer G, Jones CD, Weibel L, Denton CP, Harper JI, Woo P (2009). Validation of a protocol for the assessment of skin temperature and blood flow in childhood localised scleroderma.. Skin Res Technol, 15(3), 346 - 356. doi:10.1111/j.1600-0846.2009.00371.x
• Denton CP, Lapadula G, Mouthon L, Müller-Ladner U (2009). Renal complications and scleroderma renal crisis.. Rheumatology (Oxford), 48 Suppl 3, iii32 - iii35. doi:10.1093/rheumatology/ken483
• Shiwen X, Rajkumar V, Denton CP, Leask A, Abraham DJ (2009). Pericytes display increased CCN2 expression upon culturing.. J Cell Commun Signal, 3(1), 61 - 64. doi:10.1007/s12079-009-0053-7
• Shi-wen X, Parapuram SK, Pala D, Chen Y, Carter DE, Eastwood M, Denton CP, Abraham DJ, Leask A (2009). Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts.. Arthritis Rheum, 60(1), 234 - 241. doi:10.1002/art.24223
• Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, Carreira PE, Diaz Gonzalez F, Black CM, van den Hoogen FH (2009). An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.. Ann Rheum Dis, 68(9), 1433 - 1439. doi:10.1136/ard.2008.096123
• Denton CP, Khan K, Hoyles RK, Shiwen X, Leoni P, Chen Y, Eastwood M, Abraham DJ (2009). Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing.. J Invest Dermatol, 129(1), 194 - 204. doi:10.1038/jid.2008.171
• Ito K, Sawamura D, Goto M, Nakamura H, Nishie W, Sakai K, Natsuga K, Shinkuma S, Shibaki A, Uitto J, Denton CP, Nakajima O, Akiyama M, Shimizu H (2009). Keratinocyte-/Fibroblast-Targeted Rescue of Col7a1-Disrupted Mice and Generation of an Exact Dystrophic Epidermolysis Bullosa Model Using a Human COL7A1 Mutation. AM J PATHOL, 175(6), 2508 - 2517. doi:10.2353/ajpath.2009.090347
• Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, Denton CP, Welsh KI, Shah PL, du Bois RM, Kelleher P (2009). Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. EUR RESPIR J, 34(6), 1376 - 1382. doi:10.1183/09031936.00028209
• Chen YL, Leask A, Abraham DJ, Kennedy L, Xu SW, Denton CP, Black CM, Eastwood M (2009). Thrombospondin 1 is a key mediator of TGF beta-mediated cell contractility in systemic sclerosis via a MEK/ERK-dependent mechanism. CLIN EXP RHEUMATOL, 27(3), S83 - S83.
• Derrett-Smith EC, Khan K, Xu SW, De Winter P, Abraham D, Denton CP (2009). Pulmonary and systemic vasculopathy in a TGF-beta dependent mouse model of systemic sclerosis. CLIN EXP RHEUMATOL, 27(3), S82 - S82.
• Zweers MC, Schmitz M, Peters A, Denton CP, Fassler R, Gullberg D, Krieg T, Eckes B (2009). Dermal reconstitution following injury requires integrin-linked kinase. CLIN EXP RHEUMATOL, 27(3), S76 - S76.
• Liu SX, Kapoor M, Xu SW, Kennedy L, Denton CP, Abraham DJ, Leask A (2009). Investigation of the role of Racl in a bleomycin-induced scleroderma model using fibroblast-specific Racl knockout mice. CLIN EXP RHEUMATOL, 27(3), S72 - S72.
• Kapoor M, McCann M, Liu SX, Huh K, Denton CP, Abraham DJ, Leask A (2009). Loss of Peroxisome Proliferator-Activated Receptor gamma in Mouse Fibroblasts Results in Increased Susceptibility to Bleomycin-Induced Skin Fibrosis. ARTHRITIS RHEUM, 60(9), 2822 - 2829. doi:10.1002/art.24761
• Liu SX, Kapoor M, Denton CP, Abraham DJ, Leask A (2009). Loss of beta 1 Integrin in Mouse Fibroblasts Results in Resistance to Skin Scleroderma in a Mouse Model. ARTHRITIS RHEUM, 60(9), 2817 - 2821. doi:10.1002/art.24801
• Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009). Digital ulcers: overt vascular disease in systemic sclerosis. doi:10.1093/rheumatology/kep105
• Xu SW, Pala D, Chen YL, Eastwood M, Denton CP, Abraham DJ, Leask A (2009). TGF beta-INDUCED alpha-SMOOTH MUSCLE ACTIN EXPRESSION AND EXTRACELLULAR MATRIX CONTRACTION IN FIBROBLASTS REQUIRES TAK1. WOUND REPAIR REGEN, 17(4), A79 - A79.
• Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A (2009). LOSS OF INTEGRIN 1 RESULTS IN RESISTANCE TO BLEOMYCIN-INDUCED SCLERODERMA. WOUND REPAIR REGEN, 17(4), A72 - A72.
• Kapoor M, Shi-Wen X, Denton CP, Abraham DJ, Leask A (2009). PPAR-GAMMA AGONIST ROSIGLITAZONE ALLEVIATES THE FIBROTIC PHENOTYPE OF SKIN SCLERODERMA FIBROBLASTS. WOUND REPAIR REGEN, 17(4), A70 - A70.
• Dooley A, Xu SW, Aden N, Tranah T, Desai N, Denton CP, Black CM, Abraham DJ, Bruckdorfer R (2009). MODULATION OF TYPE I COLLAGEN SYNTHESIS AND FIBROBLAST FUNCTION IN SYSTEMIC SCLEROSIS BY THE GREEN TEA ANTIOXIDANT (-)-EPIGALLOCATECHIN-3-GALLATE.
• Lindahl G, Leoni P, Ponticos M, Xu SW, Renzoni E, Holmes A, Black CM, Denton CP, Abraham DJ (2009). CONSTITUTIVE NUCLEAR ACCUMULATION OF CBF IN SYSTEMIC SCLEROSIS PULMONARY FIBROBLASTS: A PUTATIVE TRANSCRIPTIONAL MECHANISM UNDERLYING THE FIBROTIC PHENOTYPE.
• Ong VH, Carulli MT, Xu SW, Khan K, Lindahl G, Abraham DJ, Denton CP (2009). Cross-talk between MCP-3 and TGF beta promotes fibroblast collagen biosynthesis. EXP CELL RES, 315(2), 151 - 161. doi:10.1016/j.yexcr.2008.11.001

2008

• Nihtyanova SI, Brough GM, Black CM, Denton CP (2008). Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.. Ann Rheum Dis, 67(1), 120 - 123. doi:10.1136/ard.2007.072686
• Kapoor M, Liu SX, Shi-Wen X, Huh K, McCann M, Denton CP, Woodgett JR, Abraham DJ, Leask A (2008). GSK-3 beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism (Retracted article. See vol. 118, pg. 3812, 2008). J CLIN INVEST, 118(10), 3279 - 3290. doi:10.1172/JCI35381
• Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH (2008). Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.. Eur Neurol, 59(3-4), 159 - 163. doi:10.1159/000114036
• Nihtyanova SI, Denton CP (2008). Current approaches to the management of early active diffuse scleroderma skin disease.. Rheum Dis Clin North Am, 34(1), 161 - 179. doi:10.1016/j.rdc.2007.11.005
• Carulli MT, Spagnolo P, Fonseca C, Welsh KI, Dubois RM, Black CM, Denton CP (2008). Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. J.Rheumatol., 35(5), 839 - 844.
• Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH, CAT-192 Research Group , Scleroderma Clinical Trials Consortium (2008). Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.. Arthritis Rheum, 59(5), 699 - 705. doi:10.1002/art.23564
• Leask A, Shi-Wen X, Khan K, Chen Y, Holmes A, Eastwood M, Denton CP, Black CM, Abraham DJ (2008). Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. , 121, 3459 - 3467. doi:10.1242/jcs.029215
• Penn H, Denton CP (2008). Diagnosis, management and prevention of scleroderma renal disease.. Curr Opin Rheumatol, 20(6), 692 - 696. doi:10.1097/BOR.0b013e3283108df7
• Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008). Interstitial lung disease in systemic sclerosis: a simple staging system.. Am J Respir Crit Care Med, 177(11), 1248 - 1254. doi:10.1164/rccm.200706-877OC
• Pakozdi A, Howell K, Wilson H, Fox S, Gonzalez L, Black CM, Denton CP (2008). Inhaled iloprost for the treatment of Raynaud's phenomenon. CLIN EXP RHEUMATOL, 26(4), 709 - 709.
• Khan K, Hoyles RK, Shiwen X, Howat S, Abraham DJ, Denton CP (2008). Conditional post-natal deletion of T beta RII defines a pivotal role for resident fibroblasts in the fibrotic response to lung injury.
• Derrett-Smith EC, Khan K, Shiwen X, De Winter P, Abraham D, Denton CP (2008). Pulmonary Vasculopathy in a TGF-beta dependent mouse model of scleroderma.
• Aden N, Xu SW, Nuttall A, Denton CP, Black CM, Abraham DJ, Stratton RJ (2008). Role of epidermis in scleroderma.
• Khan K, Hoyles RK, Xu SW, Abraham DJ, Denton CP (2008). Disruption of TGFbeta signalling in dermal fibroblasts delays skin wound healing and reduces fibrocyte recruitment.
• Fonseca C, Pantelidis P, Ponticos M, Abraham D, Black CM, Denton CP (2008). Analysis of polymorphisms in the endothelin axis in patients with Raynaud's phenomenon and erythromelalgia.
• Liu SX, Kapoor M, Shi-wen X, Kennedy L, Denton CP, Glogauer M, Abraham DJ, Leask A (2008). Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice. ARTHRITIS RHEUM, 58(7), 2189 - 2195. doi:10.1002/art.23595
• Cai CL, Martin JC, Sun YF, Cui L, Wang LC, Ouyang K, Yang L, Bu L, Liang XQ, Zhang XX, Stallcup WB, Denton CP, McCulloch A, Chen J, Evans SM (2008). A myocardial lineage derives from Tbx18 epicardial cells. NATURE, 454(7200), 104 - U4. doi:10.1038/nature06969
• Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, Eposs-Omeract Grp (2008). Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. ARTHRIT RHEUM-ARTHR, 59(6), 867 - 875. doi:10.1002/art.23718
• Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP (2008). Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis - Exaggerated response to alveolar epithelial injury in a novel mouse model. ARTHRITIS RHEUM, 58(4), 1175 - 1188. doi:10.1002/art.23379
• Fonseca C, Pantelidis P, Denton CP, Black CM, Abraham D (2008). Analysis of polymorphisms in the endothelin axis in patients with Raynaud's phenomenon.
• Hoyles RK, Khan K, Xu SW, Howat S, Wells AU, Abraham DJ, Black CM, Denton CP (2008). Inducible disruption of TGF signalling in resident lung fibroblasts prevents experimental fibrosis.
• Hoyles RK, Sato H, Desai S, Goh NS, Du Bois RM, Black CM, Denton CP, Wells AU (2008). KL-6, A serum marker of alveolar epithelial damage, predicts scleroderma associated lung fibrosis severity and outcome.
• Zweers MC, Schmitz M, Denton CP, Fassler R, Krieg T, Eckes B (2008). Crucial role for fibroblast integrin-linked kinase in murine wound healing.
• Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP (2008). Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?. ANN RHEUM DIS, 67(1), 105 - 109. doi:10.1136/ard.2006.067967
• Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP, Leask A, Abraham D, Stratton R (2008). Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer.. Rheumatology (Oxford), 47(12), 1754 - 1760. doi:10.1093/rheumatology/ken370
• Denton CP (2008). Renal manifestations of systemic sclerosis--clinical features and outcome assessment.. Rheumatology (Oxford), 47 Suppl 5, v54 - v56. doi:10.1093/rheumatology/ken307
• Madani G, Katz RD, Haddock JA, Denton CP, Bell JR (2008). The role of radiology in the management of systemic sclerosis.. Clin Radiol, 63(9), 959 - 967. doi:10.1016/j.crad.2008.05.007
• Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, Liu S, Carter DE, Wilcox-Adelman S, Goetinck P, Denton CP, Black CM, Pitsillides AA, Sarraf CE, Eastwood M (2008). Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.. Arthritis Rheum, 58(2), 577 - 585. doi:10.1002/art.23146
• Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, Riemekasten G, De Vita S, Morganti A, Dölberg M, Berkani O, Guillevin L, TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators (2008). Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.. Ann Rheum Dis, 67(9), 1222 - 1228. doi:10.1136/ard.2007.079921
• Baker D, Denton C (2008). Vascular Complications of Systemic Sclerosis: A Molecular Perspective. In Abraham D, Handler C, Dashwood M, Coghlan G (Ed.), Vascular Complications in Human Disease: Mechanisms and Consequences (pp. 119 - 127). : Springer-Verlag. doi:10.1007/978-1-84628-919-4_9
• Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci-Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE, Scleroderma Clinical Trials Consortium co-authors (2008). Development of a provisional core set of response measures for clinical trials of systemic sclerosis.. Ann Rheum Dis, 67(5), 703 - 709. doi:10.1136/ard.2007.078923

2007

• Woodhead FA, Sato H, Desai SR, Hoyles RK, Wells AU, Welsh KI, Denton CP, Dubois RM (2007). Systemic sclerosis-related diffuse pulmonary fibrosis quantified by high resolution computed tomography: Autoantibody and HLA associations.
• Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR (2007). Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.. Arthritis and Rheumatism, 56(1), 323 - 333. doi:10.1002/art.22289
• Shiwen X, Liu S, Kennedy L, Black CM, Denton CP, Least A, Abraham DJ (2007). Focal adhesion kinase is necessary for pro-fibrotic gene expression in normal and scleroderma fibroblasts.
• Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP (2007). Scleroderma renal crisis-patient characteristics and outcomes in 110 cases from a single centre.
• Weibel L, Howell KJ, Visentin MT, Rudiger A, Denton CP, Zulian F, Woo P, Harper JI (2007). Laser Doppler Flowmetry for assessing localized scleroderma in children. ARTHRITIS RHEUM, 56(10), 3489 - 3495. doi:10.1002/art.22920
• Eckes B, Zweers MC, Peters A, Denton CP, Fassler R, Krieg T (2007). Ablation of integrin-linked kinase in fibroblasts: Altered mechanical properties resulting in disturbed wound healing.
• Weibel L, Howell KJ, Visentin MT, Rudiger A, Denton CP, Zulian F, Woo P, Harper JI (2007). Laser Doppler flowmetry for assessing localized scleroderma (morphoea) in children.
• Rubin LJ, Black CM, Denton CP, Seibold JR (2007). Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. doi:10.1186/ar2194
• Rubin LJ, Black CM, Denton CP, Seibold JR (2007). Systemic sclerosis and related connective tissue diseases: present and future. ARTHRITIS RES THER, 9, - . doi:10.1186/ar2185
• Pope JE, Black C, Matucci-Cerinic M, Denton CP, Furst DE, Korn JH, Mayes MD, Morganti A, Seibold JR (2007). Functional correlates of reduction of digital ulcers by Bosentan therapy in patients with systemic sclerosis (SSC).
• Fonseca C, Denton CP (2007). Genetic association studies in systemic sclerosis: More evidence of a complex disease. J RHEUMATOL, 34(5), 903 - 905.
• Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA, Lehman TJA, Cerinic MM, Martini G, Ravelli A, Russo R, Cuttica R, De Oliveira SKF, Denton CP, Cozzi F, Foeldvari I, Ruperto N, Pediat Rheumatology European Soc , American Coll Rheumatology (2007). The pediatric rheumatology European Society American College of Rheumatology European league against rheumatism provisional classification criteria for juvenile systemic sclerosis. ARTHRIT RHEUM-ARTHR, 57(2), 203 - 212. doi:10.1002/art.22551
• Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, Matucci-Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM, Seibold JR (2007). Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. ANN RHEUM DIS, 66(2), 169 - 173. doi:10.1136/ard.2006.054866
• Sonnylal S, Denton CP, Zheng B, Keene DR, He RM, Adams HP, VanPelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B (2007). Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. ARTHRITIS RHEUM, 56(1), 334 - 344. doi:10.1002/art.22328
• Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A (2007). Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.. Arthritis Rheum, 56(12), 4189 - 4194. doi:10.1002/art.23134
• Denton CP (2007). Therapeutic targets in systemic sclerosis.. Arthritis Res Ther, 9 Suppl 2, S6 - . doi:10.1186/ar2190
• Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP (2007). Scleroderma renal crisis: patient characteristics and long-term outcomes.. QJM, 100(8), 485 - 494. doi:10.1093/qjmed/hcm052
• Denton CP, Nihtyanova SI (2007). Therapy of pulmonary arterial hypertension in systemic sclerosis: an update.. Curr Rheumatol Rep, 9(2), 158 - 164.
• Serednicka K, Smyth AE, Black CM, Denton CP (2007). Using a self-reported functional score to assess disease progression in systemic sclerosis.. Rheumatology (Oxford), 46(7), 1107 - 1110. doi:10.1093/rheumatology/kel432
• Xu SW, Renzoni EA, Kennedy L, Howat S, Chen YL, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A (2007). Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. MATRIX BIOL, 26(8), 625 - 632. doi:10.1016/j.matbio.2007.06.003
• Pepys MB, Terment GA, Denton CP (2007). Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Terment et al - Reply. ARTHRITIS RHEUM, 56(12), 4229 - 4230. doi:10.1002/art.23150
• Tennent GA, Dziadzio M, Triantafillidou E, Davies P, Gallimore JR, Denton CP, Pepys MB (2007). Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum, 56(6), 2013 - 2017. doi:10.1002/art.22694
• Fonseca C, Lindahl G, Ponticos M, Sestini P, Renzoni EA, Spagnolo P, Pantelidis P, Leoni P, Holmes AM, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black C, Welsh KI, du Bois RM, Abraham DJ (2007). A polymorphism in the CTGF promoter region associated with systemic sclerosis. New England Journal of Medicine, 357(12), 1210 - 1220.
• Khan K, Leoni P, Hoyles RK, Shiwen X, Abraham DJ, Denton CP (2007). Constitutive activation of p42/44 MAP Kinase signalling in mice with fibroblast-specific deletion of TRII.

2006

• Black C, Denton CP, Furst DE, Matucci-Cerinic M, Mayes MD, Popes J, Seibold JR, Morganti A, Kramer F, Korn JH (2006). Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis open label extension to a double-blind trial.
• Kingdon EJ, Mani AR, Frost MT, Denton CP, Powis SH, Black CM, Moore K (2006). Low plasma protein Nitrotyroxine levels distinguish primary Raynaud's phenomenon from scleroderma.. Annals of the Rheumatic Diseases, 65, 952 - 954.
• Lindahl GE, Holmes AM, Ponticos M, Fonseca C, Garcia P, Shi-Wen X, Denton CP, Abraham D, Black C (2006). Transcriptional mechanisms regulating CTGF gene expression in systemic sclerosis: CBF binding, Sp1 activation by ERK1/2 and repression by Sp3.
• Leask A, Kennedy L, van Beek J, Chen Y, Shi-Wen X, Denton CP, Abraham DJ, Black CM (2006). Matrix contraction by scleroderma fibroblasts requires TGF beta receptor ALK5, ras/MEK/ERK and syndecan 4.
• Denton CP, Khan K, Leoni P, Shiwen X, Abraham DJ, Black CM (2006). Key features of late-stage systemic sclerosis are replicated through conditional deletion of the type II TGF beta receptor in fibroblasts.
• Hoyles RK, Shiwen X, Lindahl GE, Khan K, Abraham DJ, Black CM, Denton CP (2006). Lung fibroblast gene expression and fibroblast - Alveolar epithelial cell cross-talk in a transgenic mouse model of systemic sclerosis.
• Ponticos M, Holmes AM, Fonseca C, Bou-Gharios G, Denton CP, Black CM, Abraham DJ (2006). A novel TGF-beta response element located in the human collagen type I alpha 2 far upstream enhancer is SMAD-independent.
• Shiwen X, Leask A, Renzoni E, Howat S, Bou-Gharios G, Pearson J, du Bois R, Denton CP, Abraham DJ, Black CM (2006). Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma.
• Aden NH, Shiwen X, Denton CP, Black CM, Abraham DJ, Stratton RJ (2006). Proteomic studies of scleroderma lesional skin show delayed keratinocyte maturation.
• Fonseca C, Lindahl GE, Ponticos M, Garcia P, Holmes A, Xu SW, Du Bois R, Renzoni E, McHugh N, Denton CP, Welsh K, Abraham D, Black C (2006). Functional polymorphism in the CTGF promoter is associated with systemic sclerosis and identifies a novel repressor site.
• Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, Denton CP, Humbert M, Matucci-Cerinic M, Seibold J, Rubin L, Furst DE (2006). Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. RHEUMATOLOGY, 45(12), 1455 - 1457. doi:10.1093/rheumatology/kel273
• Hoyles RK, Black CM, du Bois RM, Denton CP, Wells AU (2006). Autoantibody profile rather than extent of skin disease predicts severity of pulmonary fibrosis in systemic sclerosis.
• Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, Gerdin B, Denton CP, Bou-Gharios G, Black CM, Abraham DJ (2006). Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. American Journal Of Pathology, 169(6), 2254 - 2265. doi:10.2353/ajpath.2006.060196
• Denton CP, Black CM, Abraham DJ (2006). Mechanisms and consequences of fibrosis in systemic sclerosis.. Nat Clin Pract Rheumatol, 2(3), 134 - 144. doi:10.1038/ncprheum0115
• Denton CP, Humbert M, Rubin L, Black CM (2006). Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.. Ann Rheum Dis, 65(10), 1336 - 1340. doi:10.1136/ard.2005.048967
• Xu SW, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A (2006). Constitutive ALKS-independent C-jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: Evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. MOL CELL BIOL, 26(14), 5518 - 5527. doi:10.1128/MCB.00625-06
• Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C, McHugh N, Welsh KI, Du Bois RM, Denton CP, Black C, Abraham D (2006). Endothelin axis polymorphisms in patients with scleroderma. Arthritis and Rheumatism, 54(9), 3034 - 3042.
• Hoyles RK, Khan K, Shiwen X, Lindahl GE, Garcia P, Wells AU, Black CM, Abraham DJ, Denton CP (2006). Perturbed transforming growth factor beta signalling in fibroblasts increases the susceptibility of alveolar epithelial cells to injury in a novel mouse model of systemic sclerosis.
• Pope JE, Black C, Matucci-Cerinic M, Denton CP, Furst DE, Korn JH, Mayes MD, Morganti A, Seibold JR (2006). Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc)..
• Hoyles RK, Khan K, Shiwen X, Lindahl GE, Garcia P, Wells AU, Black CM, Abraham DJ, Denton CP (2006). Alveolar epithelial cell injury triggers lung fibrosis in a mouse model of scleroderma..
• Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG (2006). Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart, 92(7), 926 - 932.
• Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, Denton CP, Black CM, Coghlan JG (2006). Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. European Heart Journal, 27(12), 1485 - 1494.
• Waters CE, Xu SW, Denton CP, Abraham DJ, Pearson JD (2006). Signaling pathways regulating intercellular adhesion molecule 1 expression by endothelin 1 - Comparison with interleukin-1 beta in normal and scleroderma dermal fibroblasts. ARTHRITIS RHEUM, 54(2), 649 - 660. doi:10.1002/art.21572
• Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, Black CM, Denton CP (2006). From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. CLIN RHEUMATOL, 25(1), 3 - 15. doi:10.1007/s10067-004-1076-3
• Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ (2006). Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.. Arthritis and Rheumatism, 54(4), 1309 - 1316.
• Serednicka K, Klareskog L, Smyth AE, Black CM, Denton CP (2006). A longitudinal comparison of the Scleroderma Functional Score with the HAQ disability index.

2005

• Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005). Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis.. Arthritis Res Ther, 7(5), R1113 - R1123. doi:10.1186/ar1790
• Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, Lazaridis K, Edwards DR, Leask A, Eastwood M, Leoni P, Renzoni EA, Bou Gharios G, Abraham DJ, Black CM (2005). Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor-{beta} receptor (T{beta}RII{delta}k).. Journal of Biological Chemistry, 280(16), 16053 - 16065. doi:10.1074/jbc.M413134200
• Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP (2005). Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.. Rheumatology (Oxford), 44(12), 1518 - 1524. doi:10.1093/rheumatology/kei088
• Garg N, Shand LM, Pathak R, Myint F, Baker D, Black C, Denton CP, Hamilton G (2005). Lower and upper limb macrovascular disease is uncommon in scleroderma but is amenable to angioplasty. Rheumatology, 44, I130 - I130.
• Lagan AL, Pantelidis P, Renzoni EA, Fonseca C, Beirne P, Taegtmeyer AB, Denton CP, Black CM, Wells AU, du Bois RM, Welsh KI (2005). Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology, 44(2), 197 - 201. doi:10.1093/rheumatology/keh460
• Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, Denton CP (2005). Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.. Arthritis Rheum, 52(12), 3772 - 3782. doi:10.1002/art.21396
• Williams MH, Handler CE, Akram MR, Nair D, Denton CP, Smith CJ, Black CM, Coghlan JG (2005). Value of brain natriuretic peptide in pulmonary arterial hypertension.
• Williams MH, Das C, Handler CE, Akram MR, Denton CP, Smith CJ, Black CM, Coghlan JG (2005). Survival of patients with systemic sclerosis-associated pulmonary arterial hypertension has improved in the endothelin antagonist era.
• Williams MH, Handler CE, Akram R, Das C, Smee J, Denton CP, Nair D, Neville E, Smith SJ, Black CM, Coghlan JG (2005). Value of n-terminal pro brain natriuretic peptide in risk stratisfication and clinical management of patients with scleroderma-associated pulmonary arterial hypertension.
• Fonseca C, Lindahl GE, Garcia P, Holmes AM, Xu SW, du Bois RM, Renzoni E, Denton CP, Black CM, Abraham D (2005). Analysis of a functional polymorphism in the CTGF/CCN2 promoter in Systemic Sclerosis..
• Denton CP, Khan K, Leoni P, Xu SW, Abraham DJ, Black CM (2005). Conditional fibroblast-specific deletion of type 2 transforming growth factor beta receptor replicates digital contractures of late-stage scleroderma..
• Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG (2005). Modern treatment algorithms improve survival in systemic sclerosis associated pulmonary hypertension.
• Carulli MT, Ong VH, Abraham DJ, Coghlan GJ, Black CM, Denton CP (2005). Evaluation of CCL2 as a potential biomarker of pulmonary vascular disease in limited cutaneous systemic sclerosis.
• Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG (2005). Improved survival of systemic sclerosis-associated pulmonary arterial hypertension (SSC-PAH) in the endothelin antagonist era.
• Williams MH, Handler CE, Akram MR, Das C, Smee J, Denton CP, Nair D, Neville E, Smith CJ, Black CM, Coghlan JG (2005). Prognostic value of brain natriuretic peptide (BNP) in patients with pulmonary arterial hypertension (PAH).
• Denton CP, Black CM (2005). Targeted therapy comes of age in scleroderma.. Trends Immunol, 26(11), 596 - 602. doi:10.1016/j.it.2005.09.002

2004

• Lindahl GE, Shiwen X, Chambers RC, Denton CP, Abraham DJ, Black CM, Laurent GJ (2004). DNA BINDING-ACTIVITY OF CCAAT-BINDING FACTOR (CBF) IS STRONGLY ENHANCED IN ACTIVATED LUNG FIBROBLASTS FROM PATENTS WITH SYSTEMIC SCLEROSIS. RHEUMATOLOGY, 43, 98 - 99.
• Denton CP, Abraham DJ (2004). Transgenic analysis of scleroderma: understanding key pathogenic events in vivo.. Autoimmun Rev, 3(4), 285 - 293. doi:10.1016/j.autrev.2003.10.003
• Leask A, Denton CP, Abraham DJ (2004). Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma.. J Invest Dermatol, 122(1), 1 - 6. doi:10.1046/j.0022-202X.2003.22133.x
• Xu SW, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, Bou-Gharios G, Denton CP, du Bois RM, Black CM, Leask A, Abraham DJ (2004). Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.. J Biol Chem, 279(22), 23098 - 23103. doi:10.1074/jbc.M311430200
• Xu SW, Chen YL, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ (2004). Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Molecular Biology of the Cell, 15(6), 2707 - 2719. doi:10.1091/mbc.E03-12-0902
• Denton CP, Black CM (2004). Scleroderma--clinical and pathological advances.. Best Practice and Research Clinical Rheumatology, 18(3), 271 - 290.
• Korn JH, Mayes M, Cerinic MM, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C, RADPIDS-1 Study Grp (2004). Digital ulcers in systemic sclerosis - Prevention by treatment with bosentan, an oral endothelin receptor antagonist. ARTHRITIS RHEUM, 50(12), 3985 - 3993. doi:10.1002/art.20676
• Dziadzio M, Smith RE, Abraham DJ, Stratton RJ, Gabrielli A, Black CM, Denton CP (2004). Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review.. Clinical and Experimental Rheumatology, 22(3), 356 - 367.
• Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, Peter HH, Breedveld FC, Fibbe WE, Black C, Denton C, Koetter I, Locatelli F, Martini A, Schattenberg AV, van den Hoogen F, van de Putte L, Lanza F, Arnold R, Bacon PA, Bingham S, Ciceri F, Didier B, Diez-Martin JL, Emery P, Feremans W, Hertenstein B, Hiepe F, Luosujarvi R, Leon Lara A, Marmont A, Martinez AM, Pascual Cascon H, Bocelli-Tyndall C, Gluckman E, Gratwohl A, Tyndall A EBMT EULAR REGISTRY (2004). Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.. Annals of the Rheumatic Diseases, 63(8), 974 - 981.
• Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, Colby TV, Denton CP, Black CM, du Bois RM, Wells AU (2004). CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.. Radiology, 232(2), 560 - 567.
• Mukerjee D, Yap LB, Ong V, Denton CP, Howells K, Black CM, Coghlan JG (2004). The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.. Annals of the Rheumatic Diseases, 63(12), 1627 - 1631.

2003

• Cheng KS, Tiwari A, Boutin A, Denton CP, Black CM, Morris R, Hamilton G, Seifalian AM (2003). Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology, 42(11), 1299 - 1305.
• (2003). Differentiation of primary and secondary raynaud's disease by carotid arterial stiffness. European Journal of Vascular and Endovascular Surgery, 25(4), 336 - 341.
• Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG (2003). Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases, 62(11), 1088 - 1093.
• Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B (2003). Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. Journal of Biological Chemistry, 278(27), 25109 - 25119. doi:10.1074/jbc.M300636200
• Denton CP, Black CM (2003). Pulmonary hypertension in systemic sclerosis. Rheumatic Disease Clinics of North America, 29(2), 335 - 49, vii.
• Denton CP, Black CM, 351 Study Grp , BREATHE-1 Study Grp (2003). Bosentan for scleroderma associated pulmonary arterial hypertension - A subgroup analysis of two placebo controlled trials..
• Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP (2003). Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis and Rheumatism, 48(7), 1979 - 1991. doi:10.1002/art.11164
• Smyth AE, MacGregor AJ, Mukerjee D, Brough GM, Black CM, Denton CP (2003). A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology, 42(6), 732 - 738.

2002

• Balbir-Gurman A, Denton CP, Nichols B, Knight CJ, Nahir AM, Martin G, Black CM (2002). Non-invasive measurement of biomechanical skin properties in systemic sclerosis. Annals of the Rheumatic Diseases, 61(3), 237 - 241.
• Denton CP, Black CM (2002). Vascular scleroderma. In Asheron R, Triplett D, Cervera R (Ed.), Vascular manifestations of systemic autoimmune diseases (pp. - ). : CRC Press.
• Black CM, Denton CP (2002). Systemic sclerosis and related disorders. In Warrell DA, Cox TM, Firth JD, Benz EJ (Ed.), Oxford Textbook of Medicine (pp. - ). : Oxford University Press.
• Zheng B, Zhang Z, Black CM, de Crombrugghe B, Denton CP (2002). Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. American Journal of Pathology, 160(5), 1609 - 1617.
• Denton CP, Haddock J, Black CM (2002). Assessment of systemic sclerosis. In Isenberg DA, Renton P (Ed.), Imaging in Rheumatology (pp. - ). : Oxford University Press.

2001

• Smyth AE, Denton CP, Brough GM, Mukerjee D, Black CM (2001). Prospective comparison of three self-reported disease indices in scleroderma. RHEUMATOLOGY, 40, 115 - 115.
• Denton CP, Shiwen X, Zheng B, Rajkumar V, Abraham DJ, de Crombrugghe R, Black CM (2001). A fibrotic phenotype is induced by expression of a mutant human TGF beta receptor in transgenic mice. RHEUMATOLOGY, 40, 78 - 79.
• Denton CP, Black CM (2001). Combination therapies for systemic sclerosis.. Springer Semin Immunopathol, 23(1-2), 109 - 129.
• Xu SW, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ (2001). Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J INVEST DERMATOL, 116(3), 417 - 425.
• MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM (2001). Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. RHEUMATOLOGY (OXFORD), 40(4), 453 - 459.
• Tormey VJ, Bunn CC, Denton CP, Black CM (2001). Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology, 40(10), 1157 - 1162.
• Denton CP, Abraham DJ (2001). Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Current Opinion in Rheumatology, 13(6), 505 - 511.
• Wollheim FA, Denton CP, Abraham DJ (2001). Sixth international workshop on scleroderma research, Oxford, UK, 30 July - 2 August 2000. Arthritis Research and Therapy, 3(1), 34 - 40. doi:10.1186/ar137
• Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2001). Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology, 40(9), 1038 - 1043.
• Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B, Ramirez F, Bou-Gharios G (2001). Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene. Journal of Biological Chemistry, 276(24), 21754 - 21764.
• Denton CP, Bing Z, Xu SW, Zhang ZP, Bou-Gharios G, Eberspaecher H, Black CM, de Crombrugghe B (2001). Activation of a fibroblast-specific enhancer of the Pro alpha 2(I) collagen gene in tight-skin mice. Arthritis and Rheumatism, 44(3), 712 - 722. doi:10.1002/1529-0131(200103)44:3<712::AID-ANR121>3.0.CO;2-1

2000

• Denton CP, Howell K, Stratton RJ, Black CM (2000). Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clinical and Experimental Rheumatology, 18(4), 499 - 502.
• Denton CP, Black CM (2000). Scleroderma and related disorders: therapeutic aspects. BEST PRACT RES CL RH, 14(1), 17 - 35.